Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Hepatitis A Antibody ~32 Years Post-Vaccination with VAQTA
NCT06184230Phase 4Not yet recruiting
- Sponsor
- Best Biotech
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Whole Inactivated Vaccines
01
Overview
A Phase 4 trial of Hepatitis A virus vaccine in hepatitis A (HAV), sponsored by Best Biotech. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
Hepatitis A virus vaccine
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT06184230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184230.